Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Gets Price Target Boost from Guggenheim

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price objective raised by Guggenheim from $89.00 to $97.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim‘s price objective would suggest a potential upside of 39.95% from the company’s current price.

A number of other analysts have also recently commented on TARS. HC Wainwright upped their price target on Tarsus Pharmaceuticals from $88.00 to $106.00 and gave the stock a “buy” rating in a research report on Wednesday. Barclays started coverage on shares of Tarsus Pharmaceuticals in a report on Wednesday, September 16th. They set an “overweight” rating and a $110.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, October 15th. Jefferies Financial Group increased their price objective on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a “buy” rating in a research note on Tuesday, September 8th. Finally, The Goldman Sachs Group started coverage on shares of Tarsus Pharmaceuticals in a research report on Thursday, September 24th. They set a “buy” rating and a $116.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $104.57.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ:TARS traded up $0.24 during trading on Thursday, hitting $69.31. The company’s stock had a trading volume of 158,206 shares, compared to its average volume of 774,187. The company has a 50-day moving average of $75.12 and a 200-day moving average of $67.85. Tarsus Pharmaceuticals has a 12 month low of $53.89 and a 12 month high of $91.53. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.20 and a quick ratio of 3.17. The firm has a market cap of $3.42 billion, a price-to-earnings ratio of -4.57 and a beta of 0.34.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Tuesday, November 3rd. The company reported ($14.40) EPS for the quarter, missing analysts’ consensus estimates of ($1.46) by ($12.94). Tarsus Pharmaceuticals had a negative net margin of 102.93% and a negative return on equity of 20.22%. The business had revenue of $194.57 million for the quarter, compared to analysts’ expectations of $187.83 million. On average, sell-side analysts expect that Tarsus Pharmaceuticals will post -2.23 earnings per share for the current year.

Insider Transactions at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $90.56, for a total transaction of $905,600.00. Following the transaction, the chief executive officer owned 827,991 shares of the company’s stock, valued at approximately $74,982,864.96. This represents a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Lin sold 10,773 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $87.50, for a total value of $942,637.50. Following the completion of the sale, the insider owned 2,547 shares in the company, valued at approximately $222,862.50. The trade was a 80.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 48,031 shares of company stock worth $4,004,227. 9.64% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC lifted its position in Tarsus Pharmaceuticals by 16.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 151,606 shares of the company’s stock valued at $11,440,000 after acquiring an additional 21,277 shares during the last quarter. Alps Advisors Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 34.0% during the 3rd quarter. Alps Advisors Inc. now owns 58,130 shares of the company’s stock valued at $4,570,000 after purchasing an additional 14,765 shares during the last quarter. Covestor Ltd boosted its position in shares of Tarsus Pharmaceuticals by 40.0% in the 3rd quarter. Covestor Ltd now owns 1,095 shares of the company’s stock worth $86,000 after purchasing an additional 313 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Tarsus Pharmaceuticals in the 3rd quarter worth $185,000. Finally, Profund Advisors LLC boosted its position in shares of Tarsus Pharmaceuticals by 288.1% in the 3rd quarter. Profund Advisors LLC now owns 19,378 shares of the company’s stock worth $1,523,000 after purchasing an additional 14,385 shares in the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose about 64% year over year to a record $194.6 million, above the cited $187.8 million consensus estimate. XDEMVY surpassed one million bottles dispensed and $1 billion in cumulative sales since launch. Tarsus Q3 financial results
• Positive Sentiment: Management forecast 2026 XDEMVY sales of $715 million to $730 million, supporting expectations for continued commercial growth. HC Wainwright raised its target to $106 and Oppenheimer lifted its target to $103; both maintained favorable ratings. 2026 XDEMVY sales outlook
• Neutral Sentiment: Tarsus is deferring planned Europe and Japan filings, delaying those potential expansion opportunities. International filing plans
• Negative Sentiment: The company’s reported Q3 net loss widened to $668 million, with acquisition costs cited as a major factor. Despite the revenue growth, coverage reported that shares fell after the results, suggesting the large loss overshadowed commercial progress for investors. Q3 net loss and XDEMVY sales

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.